...NIH Funding

Dr. Rajan was absolutely right to question the current air of disdain accorded to "descriptive" studies by reviewers of grant applications.1 The ultimate goal of the National Institutes of Health is to remove the costly and painful burden of disease that prevents the full expression of a healthy human society. That being so, the ultimate model for investigation is not the HeLa cell, the mouse, or even the fruit fly, but the human being. Of course all sorts of nonhuman model systems have provide

Written byDavid Robinson
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Dr. Rajan was absolutely right to question the current air of disdain accorded to "descriptive" studies by reviewers of grant applications.1 The ultimate goal of the National Institutes of Health is to remove the costly and painful burden of disease that prevents the full expression of a healthy human society. That being so, the ultimate model for investigation is not the HeLa cell, the mouse, or even the fruit fly, but the human being. Of course all sorts of nonhuman model systems have provided a wealth of valuable and relevant information, but--for NIH grantees at any rate--these data should not be considered ends in themselves, rather, steps in an inexorable march on human disease.

Those who decry "descriptive" studies seem blinkered to this goal. Highly focused, tenacious, and ultrareductionist, they seek nothing better than molecular resolution of simple linear pathways. Thank goodness atomic resolution is for the most part unattainable ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies